Paragon 28 (FNA) Competitors

PROCEPT BioRobotics (NASDAQ:PRCT) and Paragon 28 (NYSE:FNA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, community ranking, media sentiment, risk, profitability, earnings and institutional ownership.

Which has more risk & volatility, PRCT or FNA?

PROCEPT BioRobotics has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, Paragon 28 has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500.

Does the media refer more to PRCT or FNA?

In the previous week, PROCEPT BioRobotics had 14 more articles in the media than Paragon 28. MarketBeat recorded 15 mentions for PROCEPT BioRobotics and 1 mentions for Paragon 28. PROCEPT BioRobotics' average media sentiment score of 1.56 beat Paragon 28's score of 0.43 indicating that PROCEPT BioRobotics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PROCEPT BioRobotics	13 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Paragon 28	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do insiders and institutionals hold more shares of PRCT or FNA?

89.5% of PROCEPT BioRobotics shares are held by institutional investors. Comparatively, 63.6% of Paragon 28 shares are held by institutional investors. 17.4% of PROCEPT BioRobotics shares are held by company insiders. Comparatively, 15.3% of Paragon 28 shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Do analysts rate PRCT or FNA?

PROCEPT BioRobotics currently has a consensus target price of $94.29, suggesting a potential upside of 72.12%. Paragon 28 has a consensus target price of $14.20, suggesting a potential upside of 8.60%. Given PROCEPT BioRobotics' stronger consensus rating and higher possible upside, research analysts clearly believe PROCEPT BioRobotics is more favorable than Paragon 28.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Paragon 28	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Does the MarketBeat Community believe in PRCT or FNA?

PROCEPT BioRobotics received 5 more outperform votes than Paragon 28 when rated by MarketBeat users. However, 74.47% of users gave Paragon 28 an outperform vote while only 68.97% of users gave PROCEPT BioRobotics an outperform vote.

Company	Underperform	Outperform
PROCEPT BioRobotics	Outperform Votes 40 68.97%	Underperform Votes 18 31.03%
Paragon 28	Outperform Votes 35 74.47%	Underperform Votes 12 25.53%

Which has higher earnings and valuation, PRCT or FNA?

Paragon 28 has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Paragon 28, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PROCEPT BioRobotics	$224.50M	13.38	-$105.90M	-$1.76	-31.13
Paragon 28	$256.18M	4.28	-$57.53M	-$0.63	-20.75

Is PRCT or FNA more profitable?

Paragon 28 has a net margin of -25.31% compared to PROCEPT BioRobotics' net margin of -50.07%. Paragon 28's return on equity of -37.90% beat PROCEPT BioRobotics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-50.07%	-38.57%	-26.06%
Paragon 28	-25.31%	-37.90%	-18.22%

Summary

PROCEPT BioRobotics and Paragon 28 tied by winning 9 of the 18 factors compared between the two stocks.